Vehicle to bimatoprost solution — Competitive Intelligence Brief

Vehicle to bimatoprost solution (Vehicle to bimatoprost solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin F analog. Area: Ophthalmology.

phase 3 Prostaglandin F analog Prostaglandin F receptor (FP receptor) Ophthalmology Small molecule

Target snapshot

Vehicle to bimatoprost solution (Vehicle to bimatoprost solution) — Allergan. Bimatoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vehicle to bimatoprost solution TARGET	Vehicle to bimatoprost solution	Allergan	phase 3	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)
IOPIZE© Latanoprost eyedrops	IOPIZE© Latanoprost eyedrops	University of Catanzaro	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)
Generic travoprost	Generic travoprost	Université de Sherbrooke	marketed	Prostaglandin F analog	Prostaglandin F (FP) receptor
Travoprost 0.004% ophthalmic solution	Travoprost 0.004% ophthalmic solution	Kasr El Aini Hospital	marketed	Prostaglandin F analog	Prostaglandin F (FP) receptor
Bimatoprost 0.01%	Bimatoprost 0.01%	Allergan	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)
Brand-name latanoprost	Brand-name latanoprost	CHU de Quebec-Universite Laval	marketed	Prostaglandin F analog	FP prostaglandin receptor
Dorzolamide-timolol and latanoprost	Dorzolamide-timolol and latanoprost	Laboratorios Sophia S.A de C.V.	marketed	Fixed-dose combination of carbonic anhydrase inhibitor, beta-blocker, and prostaglandin F analog	Carbonic anhydrase II (dorzolamide), beta-1 and beta-2 adrenergic receptors (timolol), prostaglandin F receptor (latanoprost)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin F analog class)

1. Allergan · 8 drugs in this class
2. CHU de Quebec-Universite Laval · 2 drugs in this class
3. Association for Innovation and Biomedical Research on Light and Image · 2 drugs in this class
4. Kasr El Aini Hospital · 1 drug in this class
5. Merck Sharp & Dohme LLC · 1 drug in this class
6. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
7. Post Graduate Institute of Medical Education and Research, Chandigarh · 1 drug in this class
8. SpyGlass Pharma, Inc. · 1 drug in this class
9. Tun Hussein Onn National Eye Hospital · 1 drug in this class
10. Universitaire Ziekenhuizen KU Leuven · 1 drug in this class